Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

@article{Cortes2007DasatinibIC,
  title={Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.},
  author={Jorge E. Cortes and Philippe Rousselot and Dong-wook Kim and Ellen Kelly Ritchie and Nelson Hamerschlak and Steven E. Coutr{\'e} and Andreas Hochhaus and François Guilhot and Giuseppe Saglio and Jane F. Apperley and Oliver G Ottmann and Neil Shah and Philipp Erben and Susan Branford and Prasheen K Agarwal and Ashwin Gollerkeri and Michele Baccarani},
  journal={Blood},
  year={2007},
  volume={109 8},
  pages={3207-13}
}
The prognosis for patients with chronic myeloid leukemia (CML) in myeloid blast crisis (MBC) or lymphoid blast crisis (LBC) remains poor. Although imatinib can induce responses in a subset of these patients, resistance to the drug develops rapidly. Dasatinib is a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases. After promising phase 1 results, we report the results of phase 2 clinical trials of dasatinib in patients with imatinib-resistant or -intolerant blast… CONTINUE READING
164 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 164 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

patients : a retrospective analysis from the French intergroup of CML ( Fi ( varphi ) - LMC GROUP )

  • N Shah, S Branford, T Hughes, J Nicoll, A Decillis, C Sawyers
  • 2006

Similar Papers

Loading similar papers…